The reference treatment involves an antibody (immunotherapy) which destroys the cells (B lymphocytes) which contain the HHV-8 virus. The antibody used is rituximab (Mabthera®). It is often associated with treatment with etoposide (vepeside®, celltop®) in an emergency, which quickly brings the symptoms under control.
It must be combined with an antiretroviral treatment in the case of HIV infection.
Relapse is possible but the disease generally responds to a second treatment.
The prognosis has improved significantly since the introduction of these new treatments.
There is a risk of the disease developing into a malignant lymph node tumour (lymphoma), but this risk has been significantly reduced since the introduction of rituximab.